Detection of new ligand-defective mutations of apolipoprotein B (apoB) will enable identification of sequences involved in binding to the LDL receptor. Genomic DNA from patients attending a lipid clinic was screened by singlestrand conformation polymorphism analysis for novel mutations in the putative LDL receptor-binding domain of apoB-100. A 46-yr-old woman of Celtic and Native American ancestry with primary hypercholesterolemia (total cholesterol [TC] 343 mg/dl; LDL cholesterol [LDL-C] 241 mg/ dl) and pronounced peripheral vascular disease was found to be heterozygous for a novel Arg3531-Cys mutation, caused by a C-T transition at nucleotide 10800. One unrelated 59-yr-old man of Italian ancestry was found with the same mutation after screening 1,560 individuals. He had coronary heart disease, a TC of 310 mg/dl, and an LDL-C of 212 mg/ dl. A total of eight individuals were found with the defect in the families of the two patients. They had an age-and sex-adjusted TC of 240±14 mg/dl and LDL-C of 169±+10 mg/dl. This compares with eight unaffected family members with age-and sex-adjusted TC of 185±12 mg/dl and LDL-C of 124±+12 mg/dl. In a dual-label fibroblast binding assay, LDL from the eight subjects with the mutation had an affinity for the LDL receptor that was 63% that of control LDL. LDL from eight unaffected family members had an affinity of 91%. By way of comparison, LDL from six patients heterozygous for the Arg3500-Gln mutation had an affinity of 36%. The percentage mass ratio of the defective Cys3531 LDL to normal LDL was 59:41, as determined using the mAb MB19 and dynamic laser light scattering. Thus, the defective LDL had accumulated in the plasma of these patients. Using this mass ratio, it was calculated that the defective Cys353, LDL particles bound with 27% of normal affinity.
Introduction
Approximately 70% of the LDL particles removed from the circulation are cleared by the liver (1) , and about 80% of this uptake is through the LDL receptor; the remainder is by a nonspecific low affinity process (1) . The high affinity interaction between LDL and the LDL receptor occurs via apolipoprotein B-100 (apoB-100) and is largely responsible for regulating plasma levels of LDL (1) . A large number of mutations (at least 150) in the LDL receptor gene have been reported that cause familial hypercholesterolemia (FH),' an autosomal codominant disorder characterized by elevated LDL levels, the frequent presence of tendon xanthomas, and premature coronary heart disease (2) . The first indication that a defect in apoB-100 can lead to a phenotype similar to FH was the observation of decreased fractional catabolic rates of autologous LDL compared with homologous LDL in five subjects (3) . It was subsequently shown that LDL from one individual possessed only 32% of normal binding affinity to LDL receptors on fibroblasts (4) . Such a defect might be expected to lead to less severe hypercholesterolemia than in FH since the rate of removal of VLDL remnants by the LDL receptor should not be affected, being mediated by apoE; hence the proportion of remnants converted to LDL should be unchanged. To date, only a single mutation of apoB-O00 has been reported that causes this disorder (familial ligand-defective apoB), a CGG to CAG change in codon 3500, resulting in the substitution of glutamine for arginine (5) . Patients with this autosomal codominant disorder, as predicted, have circulating levels of LDL cholesterol that are generally lower than those seen in FH, although there is extensive overlap. The mean level of LDL cholesterol for a total of 117 individuals heterozygous for the Arg3500-Gln mutation, in five reports, was 245 mg/dl (6) (7) (8) (9) (10) . This compares with 312 mg/dl for 153 subjects with heterozygous FH and 122 mg/dl for 313 control individuals (1 1 ).
Since it is likely that other mutations of apoB exist that cause familial ligand-defective apoB, our aim was to develop a technique to screen patients for novel mutations in the putative receptor-binding domain. We adopted a strategy using singlestrand conformational polymorphism (SSCP) analysis (12, 13) to screen genomic DNA. SSCP analysis has been used to detect mutations in a number of genes (14) (15) (16) .
The precise regions of apoB responsible for binding to the LDL receptor remain to be determined. However, the area flanking the thrombin cleavage site at residue 3249 is though to be involved (17, 18) . Within this area there are two regions, 3147-3157 and 3359-3367, both rich in positive electrostatic charge, with close homology with the LDL receptor-binding domain of apoE. These are included in the domain (residues 2835-4189) shown by antibody studies to include sequences responsible for interaction with the receptor (19) . Together with what is known about the Arg3500-+Gln mutation, this has led to a general acceptance that residues 3130-3630 account for the major part of the binding affinity (20) . Regions outside this area may also contribute (20, 21) . Using SSCP, we screened nucleotides 9213-11324 (codons 3002-3705). A portion of this region (10095-10773) was shown, in 39 hypercholesterolemic and 14 control subjects, to be highly conserved (22) .
We report the discovery of a novel apoB mutation in the putative receptor-binding domain in two unrelated kindreds, the effect on the binding of LDL to the LDL receptor in a newly described dual-label fibroblast binding assay (23) , and the mass ratio of the defective LDL to normal LDL as determined by dynamic laser light scattering. apoB gene haplotyping was performed to examine the chromosomal background of the mutation in the two families. In addition, LDL receptor gene markers were studied to determined whether there was cosegregation of this locus with the hypercholesterolemia.
Methods
Preparation of genomic DNA. Genomic DNA is routinely prepared from whole blood (24) drawn from patients that attend the Lipid Clinic of the University of California, San Francisco.
Lipid profiles. Lipid analyses were performed from blood drawn from fasting individuals as described previously (25, 26) with the exception that serum levels of HDL cholesterol and triglyceride were determined after precipitation of LDL and VLDL with MgCI2 and dextran sulfate, and levels of LDL cholesterol and triglyceride were calculated as the levels in total serum minus that in VLDL plus HDL. When appropriate, serum levels of total cholesterol and LDL cholesterol were adjusted for age (to 25 yr) and gender by nonlinear regression analysis using data in the Lipid Research Clinics Population Studies Data Book (27 taining lipoprotein-deficient serum (10%) and lovastatin (1 sg/ml; Merck & Co., West Point, PA).
After the fibroblasts had been washed twice with Dulbecco's PBS, the 1251_ and "311-LDL (0.5 ,g/ml protein each) plus HSA (0.2%) and Hepes (25 mM, pH 7.4) in DME were added. After a 3-h incubation at 4°C, maximum binding was achieved. The radioactivity in the unbound LDL ('251 and '3'I labeled) was measured in an aliquot of the medium using an automated gamma counter. After four washings at 4°C with PBS containing BSA (0.4%) and one washing with PBS alone, the cells were dissolved in NaOH (0.1 M), and their radioactive content (bound LDL) was determined. Nonspecific binding, defined as radiolabeled LDL bound in the presence of 200 tig/ml unlabeled LDL, was usually < 5% of the total binding. If the ratio of bound to free '3'I-LDL is defined as RI and that of '25I-LDL as R2, it can be shown that under the experimental conditions described, R 1/R2 is equal to K1/K2, where Kl and K2 are the equilibrium association constants of the reference LDL (13'I-LDL) and the sample LDL (25I-LDL), respectively, for the LDL receptor (23) . Values of R 1/R2 > 1 mean that the sample LDL has a lower affinity for the receptor than the reference LDL.
Measurement of mass ratios of apoB allele products. To measure the mass ratios of the two apoB allelic products, mAb MB 19, which recognizes the Ag(c/g) polymorphism (ApaLI RFLP) of apoB (30, 31 ) was used. LDL (1.021 < d < 1.055 g/ml) were isolated as previously described from the plasma of three individuals who possessed the Arg3531-Cys mutation and who were also heterozygous for the ApaLI RFLP (Thr/Ile polymorphism at residue 71) (32) . Samples were diluted to a protein concentration of 1.5 x 10-' M in 0.195 M NaCl, 0.04% EDTA, and 0.05% NaN3. Particle diameters were determined on 1-ml aliquots in quartz cuvettes at 23°C, by dynamic light scattering, using a particle sizer (Nicomp model 270, Particle Sizing Systems, Santa Barbara, CA). An equivalent amount of MB19 was added, and the particle diameters were remeasured. The sharp increase in the diameter that was observed was principally due to the dimerization of the I1e7l LDL, which has a much higher binding affinity than the Thr7, particles. A control experiment was run on each sample using mAb MB47, which caused dimerization of virtually all of the particles, in order to determine the maximum increase. The percentage of high affinity particles in each sample was then determined from a calibration curve, constructed from artificial mixtures of high and low affinity LDL isolated from Ile/Ile [Ag(c/c)] and Thr/Thr [Ag(g/g)] homozygotes, respectively. apoB gene haplotyping. 10 apoB gene polymorphic markers were analyzed by PCR. Except when noted, the PCR conditions were as previously described. We have previously reported the primers and conditions used for assaying the XbaI, MspI, and EcoRI RFLPs and the 3' hypervariable region (HVR) (25) . In the present study, the 3' HVR primers were end labeled with [y-32P] ATP (Du Pont Co.) and the PCR products were electrophoresed on 6% polyacrylamide gels. The 5' (TG)n polymorphism was assayed as described by Ludwig and McCarthy (33) . Primers 128 and 129 (58°C annealing, 3 mM MgCl2) were used for the ApaLI RFLP (nucleotide 421) (32) , and primers 131 and 146 (60°C annealing) were used for the Alul RFLP (nucleotide 1981) (34) .
BfaI was used to detect the polymorphism at nucleotide 8344 (residue 2712) (35) . Primers (41) , except that the PCR conditions were as previously described, with an annealing temperature of 54°C. apoE genotyping and phenotyping. The method described by Hixon and Vernier (42) was followed to ascertain the apoE genotypes. When possible, phenotypes were determined by isoelectric focusing of apoVLDL as previously described (26, 43 (nucleotides 10469-10990) on a strand-separating gel showed an abnormal pattern in the case of one patient (Fig. 1, lane 2 ).
An EcoRI digest of material from this individual also showed a mobility shift (Fig. 2, lane 1) , which was different from that seen in patients with the mutation at nucleotide 10708 (Arg350-OGln). To the best of our knowledge, no polymorphisms have been reported for this region. Dideoxy sequencing was performed on single-stranded DNA produced by asymmetric PCR of the patient's DNA and control DNA, using primers 41 and 94. The only difference between the patient's and the normal sequence was a single nucleotide substitution at position 10800 in codon 3531 (Fig. 3) . This changes the arginine codon CGC to cysteine, TGC. When screened for the presence of the novel NsiI site, which is introduced at nucleotide 10799 as a result of the 3531 mutation, genomic DNA samples from relatives of this patient revealed a total of six individuals with the mutation (Fig. 4) . In addition, 1,368 individuals attending the Lipid Clinic and 192 normolipidemic controls were screened for this mutation and for the 3500 mutation. One additional patient (unrelated to the first) was found with the 3531 mutation, and a total of 12 unrelated subjects were found with the 3500 mutation. Analysis of DNA from relatives of the second proband revealed one additional individual (his brother) with the 3531 mutation. Hence, in the two kindreds, a total of eight individuals were found with the 3531 mutation (Fig. 5) . The L.S. kindred is of Celtic and Native American origin, and the A.C. kindred is of Italian origin.
Lipid profiles of two kindreds. Hypercholesterolemia and a history of atherosclerosis are present in both kindreds (Table  II) . Of the 16 individuals studied, 9 have serum levels of LDL cholesterol above the 90th or 95th percentiles. As can be seen (Fig. 5) , there is no simple cosegregation of the hypercholesterolemia, in either kindred, with the 3531 mutation. However, for the eight subjects heterozygous for the 3531 mutation, the mean adjusted values for both total serum cholesterol and LDL cholesterol (Table III) Fig. 5 . As with the 3531 mutation, there is no simple cosegregation of the LDL receptor gene in these two kindreds with serum levels of cholesterol.
In the L.S. kindred (Fig. 5) , subjects II-4 and II-5 have inherited different LDL receptor alleles from their mothers (subject 1-6, the proband in this kindred). Only II-5 has the elevated lipid levels seen in her mother. She also has the 3531 apoB mutation. This does not therefore discriminate between FH or the 3531 mutation as potential causes of the hyperlipidemia seen in subjects 1-6 and II-5. However, observations in the family of the proband's sister (subject I-4) are informative in this respect (Fig. 5) . This woman has different LDL receptor haplotypes (b and e) from those (a and f) carried by subject [1] [2] [3] [4] [5] [6] (the proband) and also has an adjusted level of LDL cholesterol above the 95th percentile. Her offspring, 11-1, II-2, and 11-3, all inherited the same LDL receptor allele (haplotype b), as well as the apoB 3531 mutation, from their mother. However, although subjects II-1 and II-2 have levels of LDL cholesterol above the 95th and 90th percentiles, respectively, subject II-3 has a value in the normal range.
In the A.C. kindred, the proband (I-3) has an adjusted level of LDL cholesterol above the 95th percentile (Fig. 5) . His daughter (II-2) has inherited from her father an LDL receptor different from that inherited by her brother (Table III) indicate that the equilibrium association constant of the LDL prepared from subjects heterozygous for the 3531 mutation was 60.3±3.4% that of the reference LDL. This value was significantly different from that obtained with LDL from 11 normolipidemic control subjects (P -0.001) or from the 8 individuals in the two kindreds who did not carry the mutation (P = 0.004). By way of comparison, a value of 34.3±3.0% was found for LDL prepared from six patients who were heterozygous for the 3500 mutation (P ' 0.001 versus controls). The binding affinity of the LDL obtained from the eight unaffected members of the two kindreds was 87.3+7.1% that of the reference LDL, which was not significantly different from control LDL, which had 95.9+5.4% of the reference affinity.
The mean binding affinity of the LDL prepared from the eight subjects with the 3531 mutation was 62.9% of the mean control value, that from the eight unrelated family members was 91.0%, and that of the six subjects with the 3500 mutation was 35 35.8 Cholesterol values are in milligrams per deciliter and have been adjusted for age and sex. RI/R2 = Kl/K2, where KI is the equilibrium association constant of a reference LDL, and K2 is that of the sample LDL (values > 1.0 indicate that the sample LDL has a lower affinity than the reference LDL). * To compare the binding affinity of LDL from the three experimental groups with the mean value obtained from LDL prepared from the 11 control subjects, we set this latter value to 100%. All values are the mean±SEM. * Statistically different from controls, P c 0.001 (unpaired t test). § Statistically different from unaffected family members, P c 0.02. 11 Statistically different from unaffected family members, P = 0.004. between these two haplotypes.
As can be seen from (Table IV) . In the L. S. and A. C. kindreds, the Cys allele is associated with haplotypes E and J, respectively. The differences between these two haplotypes reside at the loci for the XbaI, BfaI (residue 2712), and Eco57I (residue 4311 ) RFLPs. (44) . Thus, based on a binding affinity of 35%, it can be calculated that the Gln3500 particles have < 10% of normal binding affinity. This is consistant with the report that LDL from one patient with the Arg3500-+Gln mutation, when highly enriched for the defective Gln35(0 variant particles, was reported to bind to the LDL receptor with < 10% of normal affinity (45) . Hence the Arg3531-+Cys mutation results in a somewhat less severe impairment of binding than does the Arg3500-+Gln mutation. This is consistent with the lipid analysis that indicates less of an increase in serum and LDL cholesterol levels as a result of the Arg3531-Cys mutation than that caused by the Arg3500--Gln mutation.
The reason for the 73% decrease in binding affinity due to the 3531 mutation is unclear. However, it is thought that the defect in binding in the case of the 3500 mutation may be the result of a conformational change in apoB-100 that involves redisposition of a number of charged residues rather than loss of a single receptor-interactive residue (46) .
We have shown that eight patients who are heterozygous for the Arg3531-+Cys mutation have a mean adjusted level of LDL cholesterol that is 66 mg/dl higher than control values and 45 mg/dl higher than the values of their unaffected family members. This difference is a reflection of other factors, possibly genetic, present in the two kindreds besides the Arg3531-+Cys mutation and reflects the lack of simple cosegregation of this defect with the hypercholesterolemia. Simple cosegregation of the LDL receptor locus with the hypercholesterolemia was not apparent, ruling out a monogenic receptor defect common to the hypercholesterolemic individuals. Additional studies should reveal many patients with the Arg3531-,Cys mutation, allowing a more accurate measure to be made of the effect it has on the level of serum cholesterol. The clinical presentation may or may not be the same as that in patients with the Arg350-+Gln mutation. The effect of the Arg3531-+Cys mutation, however, appears to be less than that of the Arg350o-+Gln mutation, which in turn is somewhat less than that of many LDL receptor gene defects seen in FH. It has previously been reported that 41 patients with the Arg3500-+Gln mutation had a mean level of total cholesterol of 269 mg/dl (45), close to the age-and gender-adjusted mean value of 265 mg/dl for the 6 patients that we studied in this report. In the earlier study (45) , LDL cholesterol levels of Arg3500-+Gln heterozygotes were 71 mg/dl higher than control values, which is somewhat lower than the 95 mg/ dl elevation seen in the present study. Innerarity and his coworkers point out that other workers have observed higher mean levels of cholesterol in Arg35os-Gln patients that are closer to values seen with FH heterozygotes, though the reasons for these differences are not clear. LDL cholesterol levels in FH heterozygotes over the age of 20 yr are elevated by 175 mg/dl over normal values (1) .
The frequency of the Arg350-+Gln mutation in an unselected population has been estimated from a four-center study, one of which was San Francisco, to be 1 in 543 (0.00184) (47) . Since we have found 12 probands with the 3500 mutation out of our clinic population of 1,368 (a frequency of 1 in 114), it follows that selection for hyperlipidemia has increased the frequency by a factor of about 4.8-fold. Hence, the occurrence of two probands with the Arg3531-_Cys mutation is compatible with a frequency in the general population in San Francisco of -1 in 3,000.
apoB haplotype analysis of two kindreds shows the presence of two different apoB Arg3531-+Cys alleles, which is perhaps not surprising in the light of the differing ethnic origins of these families. The two haplotypes differ at three markers, and since two are upstream and one is downstream of the mutation, it is likely that the mutations arose independently. Alternatively, two recombination events would have had to occur if the mutation arose only once. Two of the RFLP markers that differ, BfaI (codon 2712) and Eco57I (codon 4311), have been independently linked to the Ag(x/y) polymorphism (35, 36) , and the third (XbaI) is in linkage disequilibrium with both the BfaI and the EcoS7I RFLPs (36) .
Initially it was found that all probands with the Arg3500-+Gln mutation, in several populations in Europe and North America, had the same apoB haplotype, indicating a single mutational event (33, 48) . Recently, a different haplotype was reported in Germany, providing evidence for an independent Arg3500-+Gln mutation (49) . A unique haplotype, associated with the Gln3500 allele in a Chinese patient, indicated either an independent mutation or a recombination in the 3' end of the gene (50).
It has been estimated for other genes that the frequency of mutations in CG dinucleotides is between 10 and 20 times the average rate (51) . The Arg3531-+Cys and Arg350-Gln mutations are both transitions in CG dinucleotides, as is the MspI polymorphism in codon 3611, and all three involve substitutions for arginine residues. It would not, therefore, be surprising if other mutations in the putative apoB LDL receptor-binding domain involve mutated arginine codons. The discovery of the Arg3531-,Cys mutation and other ligand-defective mutations of apoB will enable a better understanding of the sequences involved in receptor binding. There is evidence (3, 4) that various ligand defects are significant in the etiology of primary hypercholesterolemia, and it has now been shown that certain LDL subspecies, particularly small dense LDL, have impaired ligand properties (52). Hence, it is probable that changes in the conformational disposition of apoB secondary to alterations of the lipid content of LDL may be responsible for impaired binding in a significant number of cases. In these instances no mutation in apoB will be found.
